Annex Advisory Services LLC Has $401,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Annex Advisory Services LLC boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 29.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,421 shares of the medical research company’s stock after buying an additional 1,221 shares during the period. Annex Advisory Services LLC’s holdings in Edwards Lifesciences were worth $401,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in shares of Edwards Lifesciences by 18.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock worth $129,271,000 after acquiring an additional 219,486 shares in the last quarter. Edgestream Partners L.P. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $438,000. Brighton Jones LLC grew its stake in shares of Edwards Lifesciences by 10.0% in the 2nd quarter. Brighton Jones LLC now owns 3,742 shares of the medical research company’s stock worth $346,000 after acquiring an additional 339 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in shares of Edwards Lifesciences by 29.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 13,295 shares of the medical research company’s stock worth $1,228,000 after acquiring an additional 3,049 shares in the last quarter. Finally, AE Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 14.8% in the 2nd quarter. AE Wealth Management LLC now owns 4,618 shares of the medical research company’s stock worth $427,000 after acquiring an additional 594 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 over the last three months. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Down 0.1 %

Shares of Edwards Lifesciences stock opened at $69.77 on Tuesday. The company’s 50-day moving average price is $72.06 and its 200-day moving average price is $71.18. The company has a market cap of $41.15 billion, a price-to-earnings ratio of 10.07, a PEG ratio of 3.77 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the firm posted $0.59 earnings per share. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on EW. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a research note on Thursday, January 16th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.